IGF-1 DES

Also known as: DES(1-3) IGF-1, Des-IGF-1

**Mechanism of Action** IGF-1 DES (DES(1-3) IGF-1) is a naturally occurring truncated variant of insulin-like growth factor-1, lacking the first three N-terminal amino acids. This deletion reduces its binding affinity for IGF-binding proteins (IGFBPs), resulting in enhanced bioavailability at the tissue level. The peptide exerts its effects primarily through the IGF-1 receptor (IGF-1R), activating downstream PI3K/Akt and MAPK/ERK signaling pathways. Its reduced molecular size and diminished IGFBP sequestration confer a short half-life and high local potency, making it particularly suited for site-specific anabolic actions rather than systemic growth promotion. **Key Research Findings** Preclinical studies (29 PubMed references) demonstrate that IGF-1 DES promotes localized muscle hypertrophy and myoblast proliferation with greater potency than full-length IGF-1 in vitro and in animal models. Research indicates it enhances satellite cell activation and protein synthesis in skeletal muscle, while its truncated structure limits systemic metabolic effects such as hypoglycemia. However, its short half-life necessitates repeated or localized administration for sustained effects. No human clinical trials have been conducted, and safety profiles remain uncharacterized beyond basic toxicology. **Clinical Relevance** IGF-1 DES is currently classified as a preclinical research compound with no approved medical indications. Its potential applications are limited to experimental models of muscle wasting, localized tissue repair, or athletic performance modulation, though human use is not supported by evidence. Due to its potent local effects and lack of clinical safety data, it is not recommended for therapeutic or performance-enhancing purposes outside controlled laboratory settings. For research purposes only — not medical advice.

Key data

Research & studies

Frequently asked questions

Related peptides